{
    "medicine_id": "165f67cb26341d0aa46420731b3ede73e5eb5923",
    "platform_id": "DB06825",
    "metadata": {
        "name": "Decapeptyl 0 1 MG ML Injection powder for solution",
        "composition": "0 1 MG ML Triptorelin",
        "clinical_particulars": {
            "therapeutic_indications": "Triptorelin is indicated for the palliative treatment of advanced prostate cancer",
            "contraindications": {
                "disease": "Some of the most commonly reported adverse effects of triptorelin are hot flushes reported in 58 6 of patients skeletal pain in 12 1 impotence in 7 1 and headache in 5 0 Other reported adverse effects include injection site pain general body pain leg pain fatigue hypertension dizziness diarrhea vomiting insomnia emotional lability anemia pruritus urinary tract infections and urinary retention Triptorelin is classified as Pregnancy Category X and contraindicated in pregnant women or in women who may become pregnant Hormonal changes caused by triptorelin increase the risk for pregnancy loss Studies done on pregnant rats demonstrated maternal toxicity and embryo fetal toxicities",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "The first administration of triptorelin is followed by a transient surge of follicle stimulating hormone FSH luteinizing hormone LH estradiol and testosterone The time peak and decline of testosterone in the body varies depending on the dose administered This initial surge is often responsible for worsening of prostate cancer symptoms such as urethral or bladder outlet obstruction bone pain spinal cord injury and hematuria in the early stages A sustained decrease in FSH and LH and significant reduction of testicular steroidogenesis is usually seen 2 4 weeks post initiation of therapy This result is a reduction of serum testosterone to levels which are typically seen in surgically castrated men Ultimately tissues and functions that require these hormones become inactive The effects of triptorelin can usually be reversed once the drug is discontinued",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB09066",
                        "description": "The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB09277",
                        "description": "Triptorelin may decrease effectiveness of Choline C 11 as a diagnostic agent"
                    },
                    {
                        "drugbank-id": "DB00089",
                        "description": "Triptorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent"
                    },
                    {
                        "drugbank-id": "DB00030",
                        "description": "The therapeutic efficacy of Insulin human can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00046",
                        "description": "The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00047",
                        "description": "The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00071",
                        "description": "The therapeutic efficacy of Insulin pork can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00197",
                        "description": "The therapeutic efficacy of Troglitazone can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00222",
                        "description": "The therapeutic efficacy of Glimepiride can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00284",
                        "description": "The therapeutic efficacy of Acarbose can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00359",
                        "description": "The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00412",
                        "description": "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00414",
                        "description": "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00491",
                        "description": "The therapeutic efficacy of Miglitol can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00672",
                        "description": "The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00731",
                        "description": "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00839",
                        "description": "The therapeutic efficacy of Tolazamide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00912",
                        "description": "The therapeutic efficacy of Repaglinide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00914",
                        "description": "The therapeutic efficacy of Phenformin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01015",
                        "description": "The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01016",
                        "description": "The therapeutic efficacy of Glyburide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01067",
                        "description": "The therapeutic efficacy of Glipizide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01120",
                        "description": "The therapeutic efficacy of Gliclazide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01124",
                        "description": "The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01132",
                        "description": "The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01200",
                        "description": "The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01251",
                        "description": "The therapeutic efficacy of Gliquidone can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01252",
                        "description": "The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01261",
                        "description": "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01268",
                        "description": "The therapeutic efficacy of Sunitinib can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01276",
                        "description": "The therapeutic efficacy of Exenatide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01277",
                        "description": "The therapeutic efficacy of Mecasermin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01278",
                        "description": "The therapeutic efficacy of Pramlintide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01289",
                        "description": "The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01306",
                        "description": "The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01307",
                        "description": "The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01309",
                        "description": "The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01382",
                        "description": "The therapeutic efficacy of Glymidine can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01700",
                        "description": "The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB04830",
                        "description": "The therapeutic efficacy of Buformin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB04876",
                        "description": "The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB04878",
                        "description": "The therapeutic efficacy of Voglibose can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB05115",
                        "description": "The therapeutic efficacy of NN344 can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB05819",
                        "description": "The therapeutic efficacy of NBI 6024 can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06011",
                        "description": "The therapeutic efficacy of AMG 222 can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06127",
                        "description": "The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06203",
                        "description": "The therapeutic efficacy of Alogliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06292",
                        "description": "The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06335",
                        "description": "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06655",
                        "description": "The therapeutic efficacy of Liraglutide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB08382",
                        "description": "The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB08882",
                        "description": "The therapeutic efficacy of Linagliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB08907",
                        "description": "The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB08962",
                        "description": "The therapeutic efficacy of Glibornuride can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB09022",
                        "description": "The therapeutic efficacy of Benfluorex can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB09038",
                        "description": "The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB09043",
                        "description": "The therapeutic efficacy of Albiglutide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB09045",
                        "description": "The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB09198",
                        "description": "The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB09199",
                        "description": "The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB09200",
                        "description": "The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB09201",
                        "description": "The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB09265",
                        "description": "The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB09456",
                        "description": "The therapeutic efficacy of Insulin beef can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB09564",
                        "description": "The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB11567",
                        "description": "The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB11568",
                        "description": "The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB11698",
                        "description": "The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB11723",
                        "description": "The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB11780",
                        "description": "The therapeutic efficacy of Allicin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB11824",
                        "description": "The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB11827",
                        "description": "The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB11898",
                        "description": "The therapeutic efficacy of 2 4 thiazolidinedione can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB11950",
                        "description": "The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB11992",
                        "description": "The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB12268",
                        "description": "The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB12412",
                        "description": "The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB12417",
                        "description": "The therapeutic efficacy of Anagliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB12625",
                        "description": "The therapeutic efficacy of Evogliptin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB12713",
                        "description": "The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB12781",
                        "description": "The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB12935",
                        "description": "The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB13406",
                        "description": "The therapeutic efficacy of Carbutamide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB13446",
                        "description": "The therapeutic efficacy of Guar gum can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB13675",
                        "description": "The therapeutic efficacy of Metahexamide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB13928",
                        "description": "The therapeutic efficacy of Semaglutide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB14027",
                        "description": "The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB14035",
                        "description": "The therapeutic efficacy of Englitazone can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB15171",
                        "description": "The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB15217",
                        "description": "The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00007",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Leuprolide"
                    },
                    {
                        "drugbank-id": "DB00014",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Goserelin"
                    },
                    {
                        "drugbank-id": "DB00195",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Betaxolol"
                    },
                    {
                        "drugbank-id": "DB00199",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Erythromycin"
                    },
                    {
                        "drugbank-id": "DB00207",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Azithromycin"
                    },
                    {
                        "drugbank-id": "DB00218",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Moxifloxacin"
                    },
                    {
                        "drugbank-id": "DB00243",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ranolazine"
                    },
                    {
                        "drugbank-id": "DB00263",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Sulfisoxazole"
                    },
                    {
                        "drugbank-id": "DB00321",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Amitriptyline"
                    },
                    {
                        "drugbank-id": "DB00333",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Methadone"
                    },
                    {
                        "drugbank-id": "DB00343",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Diltiazem"
                    },
                    {
                        "drugbank-id": "DB00363",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Clozapine"
                    },
                    {
                        "drugbank-id": "DB00391",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Sulpiride"
                    },
                    {
                        "drugbank-id": "DB00393",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Nimodipine"
                    },
                    {
                        "drugbank-id": "DB00420",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Promazine"
                    },
                    {
                        "drugbank-id": "DB00433",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Prochlorperazine"
                    },
                    {
                        "drugbank-id": "DB00450",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Droperidol"
                    },
                    {
                        "drugbank-id": "DB00458",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Imipramine"
                    },
                    {
                        "drugbank-id": "DB00477",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Chlorpromazine"
                    },
                    {
                        "drugbank-id": "DB00526",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Oxaliplatin"
                    },
                    {
                        "drugbank-id": "DB00537",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ciprofloxacin"
                    },
                    {
                        "drugbank-id": "DB00544",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fluorouracil"
                    },
                    {
                        "drugbank-id": "DB00556",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Perflutren"
                    },
                    {
                        "drugbank-id": "DB00568",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Cinnarizine"
                    },
                    {
                        "drugbank-id": "DB00571",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Propranolol"
                    },
                    {
                        "drugbank-id": "DB00572",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Atropine"
                    },
                    {
                        "drugbank-id": "DB00608",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Chloroquine"
                    },
                    {
                        "drugbank-id": "DB00625",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Efavirenz"
                    },
                    {
                        "drugbank-id": "DB00640",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Adenosine"
                    },
                    {
                        "drugbank-id": "DB00738",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pentamidine"
                    },
                    {
                        "drugbank-id": "DB00743",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Gadobenic acid"
                    },
                    {
                        "drugbank-id": "DB00748",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Carbinoxamine"
                    },
                    {
                        "drugbank-id": "DB00757",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dolasetron"
                    },
                    {
                        "drugbank-id": "DB00778",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Roxithromycin"
                    },
                    {
                        "drugbank-id": "DB00779",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Nalidixic acid"
                    },
                    {
                        "drugbank-id": "DB00827",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Cinoxacin"
                    },
                    {
                        "drugbank-id": "DB00836",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Loperamide"
                    },
                    {
                        "drugbank-id": "DB00889",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Granisetron"
                    },
                    {
                        "drugbank-id": "DB00904",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ondansetron"
                    },
                    {
                        "drugbank-id": "DB00922",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Levosimendan"
                    },
                    {
                        "drugbank-id": "DB00933",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mesoridazine"
                    },
                    {
                        "drugbank-id": "DB00967",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Desloratadine"
                    },
                    {
                        "drugbank-id": "DB00976",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Telithromycin"
                    },
                    {
                        "drugbank-id": "DB00978",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lomefloxacin"
                    },
                    {
                        "drugbank-id": "DB00985",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dimenhydrinate"
                    },
                    {
                        "drugbank-id": "DB01087",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Primaquine"
                    },
                    {
                        "drugbank-id": "DB01113",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Papaverine"
                    },
                    {
                        "drugbank-id": "DB01114",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Chlorpheniramine"
                    },
                    {
                        "drugbank-id": "DB01115",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Nifedipine"
                    },
                    {
                        "drugbank-id": "DB01137",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Levofloxacin"
                    },
                    {
                        "drugbank-id": "DB01155",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Gemifloxacin"
                    },
                    {
                        "drugbank-id": "DB01165",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ofloxacin"
                    },
                    {
                        "drugbank-id": "DB01182",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Propafenone"
                    },
                    {
                        "drugbank-id": "DB01193",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Acebutolol"
                    },
                    {
                        "drugbank-id": "DB01195",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Flecainide"
                    },
                    {
                        "drugbank-id": "DB01211",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Clarithromycin"
                    },
                    {
                        "drugbank-id": "DB01227",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Levacetylmethadol"
                    },
                    {
                        "drugbank-id": "DB01232",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Saquinavir"
                    },
                    {
                        "drugbank-id": "DB01242",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Clomipramine"
                    },
                    {
                        "drugbank-id": "DB01388",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mibefradil"
                    },
                    {
                        "drugbank-id": "DB01580",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Oxprenolol"
                    },
                    {
                        "drugbank-id": "DB01599",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Probucol"
                    },
                    {
                        "drugbank-id": "DB01615",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Aceprometazine"
                    },
                    {
                        "drugbank-id": "DB02638",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Terlipressin"
                    },
                    {
                        "drugbank-id": "DB04825",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Prenylamine"
                    },
                    {
                        "drugbank-id": "DB04842",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fluspirilene"
                    },
                    {
                        "drugbank-id": "DB04948",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lofexidine"
                    },
                    {
                        "drugbank-id": "DB04957",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Azimilide"
                    },
                    {
                        "drugbank-id": "DB05223",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pracinostat"
                    },
                    {
                        "drugbank-id": "DB05488",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Technetium Tc 99m ciprofloxacin"
                    },
                    {
                        "drugbank-id": "DB06160",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Garenoxacin"
                    },
                    {
                        "drugbank-id": "DB06200",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Tedisamil"
                    },
                    {
                        "drugbank-id": "DB06334",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Tucidinostat"
                    },
                    {
                        "drugbank-id": "DB06402",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Telavancin"
                    },
                    {
                        "drugbank-id": "DB06589",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pazopanib"
                    },
                    {
                        "drugbank-id": "DB06600",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Nemonoxacin"
                    },
                    {
                        "drugbank-id": "DB06603",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Panobinostat"
                    },
                    {
                        "drugbank-id": "DB06712",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Nilvadipine"
                    },
                    {
                        "drugbank-id": "DB08799",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Antazoline"
                    },
                    {
                        "drugbank-id": "DB08865",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Crizotinib"
                    },
                    {
                        "drugbank-id": "DB08903",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Bedaquiline"
                    },
                    {
                        "drugbank-id": "DB08952",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Indenolol"
                    },
                    {
                        "drugbank-id": "DB08980",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fendiline"
                    },
                    {
                        "drugbank-id": "DB08992",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Eperisone"
                    },
                    {
                        "drugbank-id": "DB09016",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Butriptyline"
                    },
                    {
                        "drugbank-id": "DB09063",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ceritinib"
                    },
                    {
                        "drugbank-id": "DB09078",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lenvatinib"
                    },
                    {
                        "drugbank-id": "DB09224",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Melperone"
                    },
                    {
                        "drugbank-id": "DB09231",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Benidipine"
                    },
                    {
                        "drugbank-id": "DB09555",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dexchlorpheniramine maleate"
                    },
                    {
                        "drugbank-id": "DB11640",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Amifampridine"
                    },
                    {
                        "drugbank-id": "DB11830",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mocetinostat"
                    },
                    {
                        "drugbank-id": "DB11841",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Entinostat"
                    },
                    {
                        "drugbank-id": "DB12141",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Gilteritinib"
                    },
                    {
                        "drugbank-id": "DB12174",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with CUDC 101"
                    },
                    {
                        "drugbank-id": "DB12286",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Simendan"
                    },
                    {
                        "drugbank-id": "DB12376",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ricolinostat"
                    },
                    {
                        "drugbank-id": "DB12523",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mizolastine"
                    },
                    {
                        "drugbank-id": "DB12565",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Abexinostat"
                    },
                    {
                        "drugbank-id": "DB12877",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Oxatomide"
                    },
                    {
                        "drugbank-id": "DB13261",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Sitafloxacin"
                    },
                    {
                        "drugbank-id": "DB13273",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Sultopride"
                    },
                    {
                        "drugbank-id": "DB13500",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Otilonium"
                    },
                    {
                        "drugbank-id": "DB13546",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Nizofenone"
                    },
                    {
                        "drugbank-id": "DB13652",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Bunaftine"
                    },
                    {
                        "drugbank-id": "DB13653",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lorcainide"
                    },
                    {
                        "drugbank-id": "DB13679",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dexchlorpheniramine"
                    },
                    {
                        "drugbank-id": "DB13791",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Penfluridol"
                    },
                    {
                        "drugbank-id": "DB14063",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dexverapamil"
                    },
                    {
                        "drugbank-id": "DB14568",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ivosidenib"
                    },
                    {
                        "drugbank-id": "DB01224",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Quetiapine"
                    },
                    {
                        "drugbank-id": "DB11718",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Encorafenib"
                    },
                    {
                        "drugbank-id": "DB01084",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Emedastine"
                    },
                    {
                        "drugbank-id": "DB15982",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Berotralstat"
                    },
                    {
                        "drugbank-id": "DB00204",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dofetilide"
                    },
                    {
                        "drugbank-id": "DB00215",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Citalopram"
                    },
                    {
                        "drugbank-id": "DB00261",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Anagrelide"
                    },
                    {
                        "drugbank-id": "DB00280",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Disopyramide"
                    },
                    {
                        "drugbank-id": "DB00283",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Clemastine"
                    },
                    {
                        "drugbank-id": "DB00308",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ibutilide"
                    },
                    {
                        "drugbank-id": "DB00313",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Valproic acid"
                    },
                    {
                        "drugbank-id": "DB00342",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Terfenadine"
                    },
                    {
                        "drugbank-id": "DB00365",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Grepafloxacin"
                    },
                    {
                        "drugbank-id": "DB00468",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Quinine"
                    },
                    {
                        "drugbank-id": "DB00489",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Sotalol"
                    },
                    {
                        "drugbank-id": "DB00530",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Erlotinib"
                    },
                    {
                        "drugbank-id": "DB00539",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Toremifene"
                    },
                    {
                        "drugbank-id": "DB00604",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Cisapride"
                    },
                    {
                        "drugbank-id": "DB00619",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Imatinib"
                    },
                    {
                        "drugbank-id": "DB00637",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Astemizole"
                    },
                    {
                        "drugbank-id": "DB00679",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Thioridazine"
                    },
                    {
                        "drugbank-id": "DB00685",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Trovafloxacin"
                    },
                    {
                        "drugbank-id": "DB00834",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mifepristone"
                    },
                    {
                        "drugbank-id": "DB00875",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Flupentixol"
                    },
                    {
                        "drugbank-id": "DB00907",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Cocaine"
                    },
                    {
                        "drugbank-id": "DB00908",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Quinidine"
                    },
                    {
                        "drugbank-id": "DB01035",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Procainamide"
                    },
                    {
                        "drugbank-id": "DB01100",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pimozide"
                    },
                    {
                        "drugbank-id": "DB01118",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Amiodarone"
                    },
                    {
                        "drugbank-id": "DB01169",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Arsenic trioxide"
                    },
                    {
                        "drugbank-id": "DB01175",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Escitalopram"
                    },
                    {
                        "drugbank-id": "DB01184",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Domperidone"
                    },
                    {
                        "drugbank-id": "DB01208",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Sparfloxacin"
                    },
                    {
                        "drugbank-id": "DB01218",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Halofantrine"
                    },
                    {
                        "drugbank-id": "DB01244",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Bepridil"
                    },
                    {
                        "drugbank-id": "DB01267",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Paliperidone"
                    },
                    {
                        "drugbank-id": "DB01356",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lithium cation"
                    },
                    {
                        "drugbank-id": "DB01405",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Temafloxacin"
                    },
                    {
                        "drugbank-id": "DB01624",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Zuclopenthixol"
                    },
                    {
                        "drugbank-id": "DB04844",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Tetrabenazine"
                    },
                    {
                        "drugbank-id": "DB04855",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dronedarone"
                    },
                    {
                        "drugbank-id": "DB04868",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Nilotinib"
                    },
                    {
                        "drugbank-id": "DB04946",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Iloperidone"
                    },
                    {
                        "drugbank-id": "DB05294",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Vandetanib"
                    },
                    {
                        "drugbank-id": "DB06176",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Romidepsin"
                    },
                    {
                        "drugbank-id": "DB06216",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Asenapine"
                    },
                    {
                        "drugbank-id": "DB06697",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Artemether"
                    },
                    {
                        "drugbank-id": "DB06708",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lumefantrine"
                    },
                    {
                        "drugbank-id": "DB09039",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Eliglustat"
                    },
                    {
                        "drugbank-id": "DB09083",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ivabradine"
                    },
                    {
                        "drugbank-id": "DB11730",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ribociclib"
                    },
                    {
                        "drugbank-id": "DB11978",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Glasdegib"
                    },
                    {
                        "drugbank-id": "DB12161",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Deutetrabenazine"
                    },
                    {
                        "drugbank-id": "DB13074",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Macimorelin"
                    },
                    {
                        "drugbank-id": "DB13725",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Terodiline"
                    },
                    {
                        "drugbank-id": "DB08881",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Vemurafenib"
                    },
                    {
                        "drugbank-id": "DB11637",
                        "description": "Triptorelin may increase the QTc prolonging activities of Delamanid"
                    },
                    {
                        "drugbank-id": "DB00104",
                        "description": "The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00107",
                        "description": "The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00187",
                        "description": "The risk or severity of QTc prolongation can be increased when Esmolol is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00188",
                        "description": "The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00196",
                        "description": "The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00220",
                        "description": "The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00230",
                        "description": "The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00245",
                        "description": "The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00270",
                        "description": "The risk or severity of QTc prolongation can be increased when Isradipine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00285",
                        "description": "The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00289",
                        "description": "The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00334",
                        "description": "The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00341",
                        "description": "The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00344",
                        "description": "The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00346",
                        "description": "The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00347",
                        "description": "The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00354",
                        "description": "The risk or severity of QTc prolongation can be increased when Buclizine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00358",
                        "description": "The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00366",
                        "description": "The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00370",
                        "description": "The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00373",
                        "description": "The risk or severity of QTc prolongation can be increased when Timolol is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00374",
                        "description": "The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00390",
                        "description": "The risk or severity of QTc prolongation can be increased when Digoxin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00398",
                        "description": "The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00405",
                        "description": "The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00424",
                        "description": "The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00427",
                        "description": "The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00434",
                        "description": "The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00467",
                        "description": "The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00487",
                        "description": "The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00503",
                        "description": "The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00529",
                        "description": "The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00540",
                        "description": "The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00543",
                        "description": "The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00555",
                        "description": "The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00582",
                        "description": "The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00593",
                        "description": "The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00613",
                        "description": "The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00622",
                        "description": "The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00674",
                        "description": "The risk or severity of QTc prolongation can be increased when Galantamine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00675",
                        "description": "The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00678",
                        "description": "The risk or severity of QTc prolongation can be increased when Losartan is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00680",
                        "description": "The risk or severity of QTc prolongation can be increased when Moricizine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00691",
                        "description": "The risk or severity of QTc prolongation can be increased when Moexipril is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00697",
                        "description": "The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00710",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00714",
                        "description": "The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00719",
                        "description": "The risk or severity of QTc prolongation can be increased when Azatadine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00726",
                        "description": "The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00734",
                        "description": "The risk or severity of QTc prolongation can be increased when Risperidone is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00753",
                        "description": "The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00808",
                        "description": "The risk or severity of QTc prolongation can be increased when Indapamide is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00817",
                        "description": "The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00818",
                        "description": "The risk or severity of QTc prolongation can be increased when Propofol is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00822",
                        "description": "The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00825",
                        "description": "The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00835",
                        "description": "The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00862",
                        "description": "The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00864",
                        "description": "The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00871",
                        "description": "The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00909",
                        "description": "The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00915",
                        "description": "The risk or severity of QTc prolongation can be increased when Amantadine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00916",
                        "description": "The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00920",
                        "description": "The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00927",
                        "description": "The risk or severity of QTc prolongation can be increased when Famotidine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00934",
                        "description": "The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00938",
                        "description": "The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00949",
                        "description": "The risk or severity of QTc prolongation can be increased when Felbamate is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00983",
                        "description": "The risk or severity of QTc prolongation can be increased when Formoterol is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00999",
                        "description": "The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01001",
                        "description": "The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01023",
                        "description": "The risk or severity of QTc prolongation can be increased when Felodipine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01026",
                        "description": "The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01036",
                        "description": "The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01044",
                        "description": "The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01054",
                        "description": "The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01059",
                        "description": "The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01069",
                        "description": "The risk or severity of QTc prolongation can be increased when Promethazine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01071",
                        "description": "The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01072",
                        "description": "The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01074",
                        "description": "The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01075",
                        "description": "The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01106",
                        "description": "The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01142",
                        "description": "The risk or severity of QTc prolongation can be increased when Doxepin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01151",
                        "description": "The risk or severity of QTc prolongation can be increased when Desipramine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01158",
                        "description": "The risk or severity of QTc prolongation can be increased when Bretylium is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01166",
                        "description": "The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01167",
                        "description": "The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01173",
                        "description": "The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01176",
                        "description": "The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01189",
                        "description": "The risk or severity of QTc prolongation can be increased when Desflurane is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01228",
                        "description": "The risk or severity of QTc prolongation can be increased when Encainide is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01233",
                        "description": "The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01236",
                        "description": "The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01238",
                        "description": "The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01239",
                        "description": "The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01246",
                        "description": "The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01254",
                        "description": "The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01259",
                        "description": "The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01263",
                        "description": "The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01274",
                        "description": "The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01396",
                        "description": "The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01403",
                        "description": "The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01426",
                        "description": "The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01591",
                        "description": "The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01611",
                        "description": "The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01620",
                        "description": "The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB01623",
                        "description": "The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB02546",
                        "description": "The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB04576",
                        "description": "The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB04695",
                        "description": "The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB04846",
                        "description": "The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB04953",
                        "description": "The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB05039",
                        "description": "The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB05246",
                        "description": "The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB05465",
                        "description": "The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06217",
                        "description": "The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06282",
                        "description": "The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06288",
                        "description": "The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06468",
                        "description": "The risk or severity of QTc prolongation can be increased when Cariporide is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06663",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06691",
                        "description": "The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06699",
                        "description": "The risk or severity of QTc prolongation can be increased when Degarelix is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06719",
                        "description": "The risk or severity of QTc prolongation can be increased when Buserelin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB06788",
                        "description": "The risk or severity of QTc prolongation can be increased when Histrelin is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB07780",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Farnesyl diphosphate"
                    },
                    {
                        "drugbank-id": "DB07841",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Geranylgeranyl diphosphate"
                    },
                    {
                        "drugbank-id": "DB08808",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Bupranolol"
                    },
                    {
                        "drugbank-id": "DB08815",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lurasidone"
                    },
                    {
                        "drugbank-id": "DB08864",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Rilpivirine"
                    },
                    {
                        "drugbank-id": "DB08871",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08893",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Mirabegron"
                    },
                    {
                        "drugbank-id": "DB08912",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dabrafenib"
                    },
                    {
                        "drugbank-id": "DB08936",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Chlorcyclizine"
                    },
                    {
                        "drugbank-id": "DB08972",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Flumequine"
                    },
                    {
                        "drugbank-id": "DB09080",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Olodaterol"
                    },
                    {
                        "drugbank-id": "DB09082",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Vilanterol"
                    },
                    {
                        "drugbank-id": "DB09089",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Trimebutine"
                    },
                    {
                        "drugbank-id": "DB09090",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pinaverium"
                    },
                    {
                        "drugbank-id": "DB09167",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dosulepin"
                    },
                    {
                        "drugbank-id": "DB09229",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Aranidipine"
                    },
                    {
                        "drugbank-id": "DB09235",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Efonidipine"
                    },
                    {
                        "drugbank-id": "DB09236",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lacidipine"
                    },
                    {
                        "drugbank-id": "DB09239",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Niguldipine"
                    },
                    {
                        "drugbank-id": "DB09488",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Acrivastine"
                    },
                    {
                        "drugbank-id": "DB11390",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Coumaphos"
                    },
                    {
                        "drugbank-id": "DB11397",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dichlorvos"
                    },
                    {
                        "drugbank-id": "DB11408",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Famphur"
                    },
                    {
                        "drugbank-id": "DB11412",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fenthion"
                    },
                    {
                        "drugbank-id": "DB11443",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Orbifloxacin"
                    },
                    {
                        "drugbank-id": "DB11448",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Phosmet"
                    },
                    {
                        "drugbank-id": "DB11491",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Sarafloxacin"
                    },
                    {
                        "drugbank-id": "DB11511",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Difloxacin"
                    },
                    {
                        "drugbank-id": "DB11591",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Bilastine"
                    },
                    {
                        "drugbank-id": "DB11614",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Rupatadine"
                    },
                    {
                        "drugbank-id": "DB11742",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ebastine"
                    },
                    {
                        "drugbank-id": "DB11770",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Talinolol"
                    },
                    {
                        "drugbank-id": "DB11774",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pazufloxacin"
                    },
                    {
                        "drugbank-id": "DB11785",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Anisodamine"
                    },
                    {
                        "drugbank-id": "DB11891",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with CUDC 907"
                    },
                    {
                        "drugbank-id": "DB11892",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Prulifloxacin"
                    },
                    {
                        "drugbank-id": "DB11943",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Delafloxacin"
                    },
                    {
                        "drugbank-id": "DB12093",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Tetrahydropalmatine"
                    },
                    {
                        "drugbank-id": "DB12231",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Temefos"
                    },
                    {
                        "drugbank-id": "DB12245",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Triclabendazole"
                    },
                    {
                        "drugbank-id": "DB12645",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Givinostat"
                    },
                    {
                        "drugbank-id": "DB12712",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pilsicainide"
                    },
                    {
                        "drugbank-id": "DB12766",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Cicletanine"
                    },
                    {
                        "drugbank-id": "DB12923",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Gallopamil"
                    },
                    {
                        "drugbank-id": "DB13358",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Cibenzoline"
                    },
                    {
                        "drugbank-id": "DB13488",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Bencyclane"
                    },
                    {
                        "drugbank-id": "DB13555",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Prajmaline"
                    },
                    {
                        "drugbank-id": "DB13627",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Oxolinic acid"
                    },
                    {
                        "drugbank-id": "DB13651",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lorajmine"
                    },
                    {
                        "drugbank-id": "DB13691",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Acetyldigoxin"
                    },
                    {
                        "drugbank-id": "DB13744",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Piromidic acid"
                    },
                    {
                        "drugbank-id": "DB13766",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Lidoflazine"
                    },
                    {
                        "drugbank-id": "DB13772",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Rufloxacin"
                    },
                    {
                        "drugbank-id": "DB13823",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Pipemidic acid"
                    },
                    {
                        "drugbank-id": "DB14185",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Aripiprazole lauroxil"
                    },
                    {
                        "drugbank-id": "DB14713",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Inotersen"
                    },
                    {
                        "drugbank-id": "DB01601",
                        "description": "The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00845",
                        "description": "The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB11796",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fostemsavir"
                    },
                    {
                        "drugbank-id": "DB00751",
                        "description": "The risk or severity of QTc prolongation can be increased when Epinastine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB11853",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Relugolix"
                    },
                    {
                        "drugbank-id": "DB00331",
                        "description": "The therapeutic efficacy of Metformin can be decreased when used in combination with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00656",
                        "description": "The risk or severity of QTc prolongation can be increased when Trazodone is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB11986",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Entrectinib"
                    },
                    {
                        "drugbank-id": "DB11642",
                        "description": "Triptorelin may increase the QTc prolonging activities of Pitolisant"
                    },
                    {
                        "drugbank-id": "DB12825",
                        "description": "Lefamulin may increase the QTc prolonging activities of Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00557",
                        "description": "The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB00246",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ziprasidone"
                    },
                    {
                        "drugbank-id": "DB00502",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Haloperidol"
                    },
                    {
                        "drugbank-id": "DB00472",
                        "description": "The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Triptorelin"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}